Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 8, 2012, Pages 1234-1241

  Sarafidis, Pantelis A ^a   Blacklock, Rochelle ^a   Wood, Eleri ^a   Rumjon, Adam ^a   Simmonds, Shanique ^a   Fletcher Rogers, Jessica ^a   Ariyanayagam, Rachel ^a   Al Yassin, Aziza ^a   Sharpe, Claire ^a   Vinen, Katie ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BICARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; UREA;

AGED; ARTICLE; BICARBONATE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMORBIDITY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIETITIAN; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL; UREA BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; KIDNEY; LOGISTIC MODELS; LONDON; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POTASSIUM; POTASSIUM, DIETARY; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SODIUM BICARBONATE; TIME FACTORS;

EID: 84864801182     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01150112     Document Type: Article

References (28)

1. Allon M: Hyperkalemia in end-stage renal disease: Mechanisms and management. J Am Soc Nephrol 6: 1134-1142, 1995
2. Acker CG, Johnson JP, Palevsky PM, Greenberg A: Hyperkalemia in hospitalized patients: Causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 158: 917-924, 1998
3. Weiner ID, Wingo CS: Hyperkalemia: A potential silent killer. J Am Soc Nephrol 9: 1535-1543, 1998
4. Perazella MA: Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med 109: 307-314, 2000
5. Palmer BF: A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis 56: 387-393, 2010
6. Siamopoulos KC, ElisafM, Katopodis K: Iatrogenic hyperkalaemia-points to consider in diagnosis and management. Nephrol Dial Transplant 13: 2402-2406, 1998
7. Sarafidis PA, Georgianos PI, Lasaridis AN: Diuretics in clinical practice. Part II: Electrolyte and acid-base disorders complicating diuretic therapy. Expert Opin Drug Saf 9: 259-273, 2010
8. Sarafidis PA, Khosla N, Bakris GL: Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49: 12-26, 2007
9. Weir MR: Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens 12: 195S-203S, 1999
10. Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. NEngl JMed 351: 585-592, 2004
11. Kunz R, Friedrich C, Wolbers M, Mann JF:Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30-48, 2008
12. Toto RD: Aldosterone blockade in chronic kidney disease: Can it improve outcome? Curr Opin Nephrol Hypertens 19: 444-449, 2010
13. Sica DA, Hess M: Pharmacotherapy in congestive heart failure: Aldosterone receptor antagonism: Interface with hyperkalemia in heart failure. Congest Heart Fail 10: 259-264, 2004
14. Sarafidis PA, Bakris GL: Resistant hypertension: An overview of evaluation and treatment. J Am Coll Cardiol 52: 1749-1757, 2008
15. Bakris GL, Hart P, Ritz E: Beta blockers in the management of chronic kidney disease. Kidney Int 70: 1905-1913, 2006
16. Takaichi K, Takemoto F, Ubara Y, Mori Y: The clinically significant estimated glomerular filtration rate for hyperkalemia. Intern Med 47: 1315-1323, 2008
17. Drion I, Joosten H, Dikkeschei LD, Groenier KH, Bilo HJ: eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. Eur J Intern Med 20: 722-727, 2009
18. MoranneO, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M'rad MB, Jacquot C, Houillier P, Stengel B, Fouqueray B; NephroTest Study Group: Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20: 164-171, 2009
19. Weinberg JM, Appel LJ, BakrisG, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA; African American Study of Hypertension and Kidney Disease Collaborative Research Group: Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 169: 1587-1594, 2009
20. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC: The frequency of hyperkalemia and its significance in chronic kidney disease. Arch InternMed 169: 1156-1162, 2009
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
22. Textor SC, Bravo EL, Fouad FM, Tarazi RC: Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 73: 719-725, 1982
23. Gennari FJ, Segal AS: Hyperkalemia: An adaptive response in chronic renal insufficiency. Kidney Int 62: 1-9, 2002
24. Reardon LC, MacphersonDS: Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 158: 26-32, 1998
25. Juurlink DN, MamdaniMM, LeeDS, KoppA, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551, 2004
26. Khosla N, Kalaitzidis R, Bakris GL: Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 30: 418-424, 2009
27. Lu XH, Su CY, Sun LH, Chen W, Wang T: Implementing continuous quality improvement process in potassium management in peritoneal dialysis patients. J Ren Nutr 19: 469-474, 2009
28. Surawicz B, Chlebus H, Mazzoleni A: Hemodynamic and electrocardiographic effects of hyperpotassemia. Differences in response to slow and rapid increases in concentration of plasma K. Am Heart J 73: 647-664, 1967